A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE I CLINICAL STUDY ON THE HEPATIC UPTAKE, PHARMACOKINETICS, SAFETY AND TOLERANCE OF A NEW ORAL PENTAMIDINE FORMULATION IN HEPATOCELLULAR CARCINOMA SUBJECTS UNDERGOING THERMAL ABLATION

Intervention/treatment:
PENTAMIDINE
Medical condition:
HEPATOCELLULAR CARCINOMA
Protocol code:
OCZ103-300-1401
Control number:
174837
Status:
Closed
Approved:
June 13, 2014
Trial phase:
Phase 1
For more information:
ClinicalTrials.gov - NCT02210182
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
ONCOZYME PHARMA INC

Locations

Alberta

Dr. Kelly Burak
Calgary, Alberta, T2N4Z6

Ontario

Dr Morris Sherman
Toronto, Ontario, M5G 2N2

Quebec

Dr Marc Bilodeau
Montreal, Quebec, H2X 3J4
Did you find what you were looking for?